Stockscreener 앱 받기
25.28
0.36%
0.09
시장 영업 전:
25.11
-0.17
-0.67%
전일 마감가:
$25.19
열려 있는:
$25.46
하루 거래량:
1.60M
Relative Volume:
1.55
시가총액:
$2.41B
수익:
-
순이익/손실:
$-115.88M
주가수익비율:
-16.34
EPS:
-1.5468
순현금흐름:
$-104.72M
1주 성능:
-10.13%
1개월 성능:
-2.84%
6개월 성능:
+34.25%
1년 성능:
+45.20%
1일 변동 폭
$23.84
$26.40
1주일 범위
$23.84
$30.04
52주 변동 폭
$14.90
$38.12
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
EWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
25.28 | 2.41B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.3%Time to Sell? - MarketBeat
Ratios Uncovered: Breaking Down Edgewise Therapeutics Inc (EWTX)’s Trailing Twelve Months Metrics - The Dwinnex
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference - BioSpace
Edgewise Therapeutics chief scientific officer sells $6,004 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CEO Kevin Koch sells $3,000 in stock By Investing.com - Investing.com South Africa
Scotiabank Begins Coverage on Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics chief scientific officer sells $6,004 in stock - Investing.com
Breakthrough Drug Sevasemten Delivers Positive Results for Becker Muscular Dystrophy Patients - StockTitan
Edgewise Therapeutics Sees Unusually Large Options Volume (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 4.9%Still a Buy? - MarketBeat
Edgewise Therapeutics: More Expensive Now, But Much More Derisked (NASDAQ:EWTX) - Seeking Alpha
Piper Sandler maintains $51 target on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Holdings Lessened by Candriam S.C.A. - MarketBeat
Why Is Edgewise Therapeutics Inc (NASDAQ: EWTX) Falling? - Stocks Register
Edgewise Therapeutics (NASDAQ:EWTX) Research Coverage Started at Scotiabank - Defense World
Trend Tracker for (EWTX) - Stock Traders Daily
Q1 EPS Forecast for Edgewise Therapeutics Lowered by Analyst - MarketBeat
Equities Analysts Issue Forecasts for EWTX FY2026 Earnings - MarketBeat
Scotiabank Initiates Coverage of Edgewise Therapeutics (EWTX) with Sector Outperform Recommendation - Nasdaq
Edgewise Therapeutics Sees Unusually High Options Volume (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics' (EWTX) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Scotiabank sets $50 target for Edgewise Therapeutics stock - Investing.com India
Wedbush Lowers Earnings Estimates for Edgewise Therapeutics - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Leerink Partnrs Brokers Decrease Earnings Estimates for EWTX - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Announces Quarterly Earnings Results - MarketBeat
Handelsbanken Fonder AB Purchases Shares of 21,800 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Ratios Revealed: Decoding Edgewise Therapeutics Inc (EWTX)’s Financial Health - The Dwinnex
Edgewise Therapeutics (NASDAQ:EWTX) Receives Outperform Rating from Royal Bank of Canada - Defense World
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025 - Joplin Globe
Edgewise Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Edgewise Therapeutics boosted R&D spending in final quarter of 2024 - BizWest
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q4 Total Operating Expenses $45.5M - Marketscreener.com
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q4 Net Loss $0.42 a Share, vs. FactSet Est of $0.37 Loss - Marketscreener.com
Edgewise Therapeutics reports Q4 EPS (42c), consensus (42c) - TipRanks
Edgewise Therapeutics, Inc. SEC 10-K Report - TradingView
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - Business Wire
Can Edgewise's $470M War Chest and Muscular Dystrophy Pipeline Deliver for Biotech Investors? - StockTitan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Edgewise Therapeutics (EWTX) Shares Cross Below 200 DMA - Nasdaq
Edgewise Therapeutics (NASDAQ:EWTX) Trading 5.9% HigherShould You Buy? - MarketBeat
Edgewise Therapeutics (EWTX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엣지와이즈 주식 (EWTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Mar 07 '25 |
Sale |
30.02 |
200 |
6,004 |
14,863 |
| KOCH KEVIN | President and CEO |
Mar 07 '25 |
Option Exercise |
0.18 |
100 |
18 |
14,578 |
| KOCH KEVIN | President and CEO |
Mar 07 '25 |
Sale |
30.00 |
100 |
3,000 |
14,478 |
| Russell Alan J | Chief Scientific Officer |
Feb 05 '25 |
Option Exercise |
0.18 |
8,015 |
1,443 |
22,878 |
| Russell Alan J | Chief Scientific Officer |
Feb 06 '25 |
Option Exercise |
0.18 |
1,200 |
216 |
16,063 |
| Russell Alan J | Chief Scientific Officer |
Feb 05 '25 |
Sale |
30.02 |
8,015 |
240,623 |
14,863 |
| Russell Alan J | Chief Scientific Officer |
Feb 06 '25 |
Sale |
30.13 |
1,200 |
36,153 |
14,863 |
| KOCH KEVIN | President and CEO |
Feb 06 '25 |
Option Exercise |
13.11 |
900 |
11,799 |
15,378 |
| KOCH KEVIN | President and CEO |
Feb 05 '25 |
Option Exercise |
0.18 |
8,636 |
1,554 |
23,114 |
| KOCH KEVIN | President and CEO |
Feb 05 '25 |
Sale |
30.03 |
8,636 |
259,298 |
14,478 |
1.39%
0.55%
자본화:
|
볼륨(24시간):